Promius launches atopic dermatitis product in US
This article was originally published in Scrip
Promius Pharma, a wholly owned US subsidiary ofDr Reddy's Laboratories, has launched its first product, a novel treatment for atopic dermatitis, on the US market. The prescription product, EpiCeram skin barrier emulsion, is based on scientific advances in the understanding of the skin barrier and its role in the pathogenesis of atopic dermatitis. It provides an optimal 3:1:1 ratio of ceramides, free fatty acids and cholesterol to help repair the damaged skin barrier and relieve the signs and symptoms of atopic dermatitis, the company says. The US market for atopic dermatitis is estimated at $400 million and the disease affects more than 15 million patients in the US. Promius, which expects to initially focus on the branded dermatology market, plans to launch three in-licensed and co-developed products in 2008-09. The company's current portfolio includes topical products for psoriasis, atopic dermatitis and seborrheic dermatitis.
You may also be interested in...
Cipla gets US FDA go-ahead earlier than anticipated for first generic of Merck’s Proventil, setting the stage for increased competition in the albuterol segment, where demand is up amid the coronavirus pandemic.
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.